Athira Pharma amends bylaws for SEC Rule 14a-19 compliance and advance notice updates

LeonaBio, Inc.

Board approved amended and restated bylaws effective November 15, 2022.
Changes comply with new SEC Rule 14a-19 (universal proxy) and enhance advance notice for stockholder proposals and nominations.
Bylaws updated for recent Delaware General Corporation Law amendments on stockholder meetings.
Modifications to officer appointments, board committee procedures, and forum selection clause.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

LeonaBio, Inc.: Amended and restated bylaws to comply with Rule 14a-19 and enhance advance notice procedures for stockholder proposals and nominations, along with other updates (effective 2022-11-15).

Change: bylaw amendment
Effective: 2022-11-15

Exact text from the filing

On November 15, 2022, the board of directors (the “Board”) of Athira Pharma, Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”) of the Company, effective immediately.

View on SEC.gov

Browse all governance changes →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-025442

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.